Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis
- PMID: 17911598
- DOI: 10.4049/jimmunol.179.8.5126
Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis
Abstract
Negative immunoregulation is a major barrier to successful cancer immunotherapy. The NKT cell is known to be one such regulator. In this study we explored the roles of and interaction between the classical type I NKT cell and the poorly understood type II NKT cell in the regulation of tumor immunity. Selective stimulation of type II NKT cells suppressed immunosurveillance, whereas stimulation of type I NKT cells protected against tumor growth even when responses were relatively skewed toward Th2 cytokines. When both were stimulated simultaneously, type II NKT cells appeared to suppress the activation in vitro and protective effect in vivo of type I NKT cells. In the absence of type I, suppression by type II NKT cells increased, suggesting that type I cells reduce the suppressive effect of type II NKT cells. Thus, in tumor immunity type I and type II NKT cells have opposite and counteractive roles and define a new immunoregulatory axis. Alteration of the balance between the protective type I and the suppressive type II NKT cell may be exploited for therapeutic intervention in cancer.
Similar articles
-
NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis.Trends Immunol. 2007 Nov;28(11):491-6. doi: 10.1016/j.it.2007.05.008. Epub 2007 Oct 25. Trends Immunol. 2007. PMID: 17964217 Review.
-
A novel immunoregulatory axis of NKT cell subsets regulating tumor immunity.Cancer Immunol Immunother. 2008 Nov;57(11):1679-83. doi: 10.1007/s00262-008-0495-4. Epub 2008 Mar 28. Cancer Immunol Immunother. 2008. PMID: 18369622 Free PMC article.
-
A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance.J Exp Med. 2005 Dec 19;202(12):1627-33. doi: 10.1084/jem.20051381. J Exp Med. 2005. PMID: 16365146 Free PMC article.
-
Up-regulation of CD1d expression restores the immunoregulatory function of NKT cells and prevents autoimmune diabetes in nonobese diabetic mice.J Immunol. 2004 May 15;172(10):5908-16. doi: 10.4049/jimmunol.172.10.5908. J Immunol. 2004. PMID: 15128771
-
Tissue-Specific Roles of NKT Cells in Tumor Immunity.Front Immunol. 2018 Aug 15;9:1838. doi: 10.3389/fimmu.2018.01838. eCollection 2018. Front Immunol. 2018. PMID: 30158927 Free PMC article. Review.
Cited by
-
Balance is a key for happiness.Oncoimmunology. 2013 May 1;2(5):e24211. doi: 10.4161/onci.24211. Oncoimmunology. 2013. PMID: 23762801 Free PMC article.
-
The dual role of complement in cancer and its implication in anti-tumor therapy.Ann Transl Med. 2016 Jul;4(14):265. doi: 10.21037/atm.2016.06.26. Ann Transl Med. 2016. PMID: 27563652 Free PMC article. Review.
-
NKT cells stimulated by long fatty acyl chain sulfatides significantly reduce the incidence of type 1 diabetes in nonobese diabetic mice [corrected].PLoS One. 2012;7(5):e37771. doi: 10.1371/journal.pone.0037771. Epub 2012 May 23. PLoS One. 2012. PMID: 22649557 Free PMC article.
-
Recent Development in NKT-Based Immunotherapy of Glioblastoma: From Bench to Bedside.Int J Mol Sci. 2022 Jan 24;23(3):1311. doi: 10.3390/ijms23031311. Int J Mol Sci. 2022. PMID: 35163235 Free PMC article. Review.
-
The Role of Invariant NKT in Autoimmune Liver Disease: Can Vitamin D Act as an Immunomodulator?Can J Gastroenterol Hepatol. 2018 Jun 26;2018:8197937. doi: 10.1155/2018/8197937. eCollection 2018. Can J Gastroenterol Hepatol. 2018. PMID: 30046564 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases